(Pop Busui et al., 2026) Who was studied: 9650 people with type 2 diabetes plus established atherosclerotic cardiovascular disease and or chronic kidney disease, enrolled at 444 centers across 33 countries, median age 66, followed for about 47.5 months
Acetylcarnitine levels under physiological and pathological conditions Several studies have shown that long-term use of acetylcarnitine reduces symptoms of chronic fatigue and improves the general condition in patients with chronic fatigue syndrome (Table 1, [79, 81, 142])
The mechanism involves glucose-dependent insulin secretion, meaning insulin release occurs primarily when blood glucose levels are elevated, thereby reducing the risk of hypoglycemia when used as monotherapy
van Erp H, Bryant FM, Martin-Moreno J, Michaelson LV, Eastmond PJ (2021) Production of the infant formula ingredient 1,3-olein-2-palmitin in Arabidopsis thaliana seeds
doi: 10.1001/jamanetworkopen.2021.0242 4 SuwanchatchaiCBuaphanSKhuanchareeK